Oramed Pharmaceuticals (ORMP) Q2 2025 earnings summary

Executive summary

• Achieved net income of $5.6M for the six months ended June 30, 2025, compared to $10.7M in the prior year period, driven by financial income from investments and a one-time revenue recognition from a license agreement settlement.

• Revenue of $2.0M recognized from the HTIT License Agreement following a waiver of claims as part of a joint venture agreement; no comparable revenue in the prior year.

• Significant investments made in Alpha Tau Medical Ltd. and real estate, diversifying the asset base and aiming for long-term value creation.

Financial highlights

• Six-month revenue: $2.0M (vs. $0M prior year); net income: $5.6M (vs. $10.7M prior year); EPS: $0.14 basic, $0.13 diluted.

• Financial income for six months: $12.8M, primarily from revaluation of Alpha Tau and Scilex investments.

• Cash and cash equivalents at June 30, 2025: $15.8M; short-term deposits: $22.9M; working capital surplus: $95.3M.

• Operating cash outflow: $7.1M; investing cash outflow: $31.2M; financing cash outflow: $0.4M for share repurchases.

Outlook and guidance

• Plans to increase R&D spending with the anticipated initiation of a revised Phase 3 clinical trial, though JV delays with HTIT have paused immediate trial activities.

• Current cash resources expected to support planned activities and expenditures for at least the next 12 months.